Candel Therapeutics, Inc.
General ticker "CADL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $331.6M (TTM average)
Candel Therapeutics, Inc. follows the US Stock Market performance with the rate: 53.0%.
Estimated limits based on current volatility of 3.5%: low 9.31$, high 9.97$
Factors to consider:
- Total employees count: 55 (+44.7%) as of 2025
- Top business risk factors: Operational and conduct risks, Regulatory and compliance, Financing availability, Clinical trial delays, Manufacturing scale up
- Current price 34.0% above estimated high
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.86$, 7.60$]
- 2026-12-31 to 2027-12-31 estimated range: [2.57$, 6.93$]
Financial Metrics affecting the CADL estimates:
- Positive: with PPE of -8.1 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of -0.18 > -0.60
- Positive: 19.19 < Shareholder equity ratio, % of 41.47 <= 42.57
- Negative: negative Net income
- Positive: Inventory ratio change, % of 0 <= 0
Short-term CADL quotes
Long-term CADL plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $38.39MM | $33.37MM | $48.27MM |
| Operating Income | $-38.39MM | $-33.37MM | $-48.27MM |
| Non-Operating Income | $0.45MM | $-21.81MM | $10.08MM |
| Interest Expense | $2.60MM | $2.09MM | $2.12MM |
| R&D Expense | $24.51MM | $19.31MM | $30.50MM |
| Income(Loss) | $-37.94MM | $-55.18MM | $-38.18MM |
| Net Income(Loss)* | $-37.94MM | $-55.18MM | $-38.18MM |
| Stockholders Equity | $12.74MM | $66.33MM | $51.92MM |
| Assets | $41.20MM | $106.87MM | $125.19MM |
| Operating Cash Flow | $-34.24MM | $-27.02MM | $-38.31MM |
| Capital expenditure | $0.46MM | $0.02MM | $0.59MM |
| Investing Cash Flow | $-0.28MM | $-0.02MM | $-0.56MM |
| Financing Cash Flow | $-0.12MM | $94.28MM | $56.10MM |
| Earnings Per Share** | $-1.31 | $-1.74 | $-0.72 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.